s-propargylcysteine profile

S-propargylcysteine: a memory enhancing agent; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	22789047
CHEMBL ID	1288481
SCHEMBL ID	3247513
MeSH ID	M0555437

Synonym
(l)-3-(propargylsulfenyl)-alanine
CHEMBL1288481
(r)-2-amino-3-(prop-2-yn-1-ylthio)propanoic acid
AKOS015949273
AKOS010389150
3262-64-4
(r)-2-amino-3-(2-propynylthio)propanoic acid
(r)-2-amino-3-(prop-2-ynylthio)propanoic acid
J-502176
SCHEMBL3247513
DTXSID20628366
s-prop-2-yn-1-yl-l-cysteine
s-propargylcysteine
CS-W001538
sprc
zyz-802
s-propargyl-cysteine
(r)-2-amino-3-(prop-2-yn-1-ylthio)propanoicacid
AS-75762
HY-W001538

Excerpt	Reference	Relevance
" Using the validated assay, the pharmacokinetic properties of SPRC in rats were investigated."	( Determination of S-propargyl-cysteine in rat plasma by mixed-mode reversed-phase and cation-exchange HPLC-MS/MS method and its application to pharmacokinetic studies. Cai, W; Gu, Y; Liu, H; Ma, G; Shao, T; Yang, P; Zhang, L; Zhang, P; Zheng, Y; Zhu, Q; Zhu, Y, 2011)	0.37
" Intravenous administration of SPRC (single dose) to beagle dogs gave a mean plasma half-life of 14."	( Bioavailability and pharmacokinetics of S-propargyl-L-cysteine, a novel cardioprotective agent, after single and multiple doses in Beagle dogs. Cai, W; Liu, H; Ma, G; Xu, J; Zhang, J; Zhang, P; Zheng, Y; Zhu, Q; Zhu, Y, 2012)	0.38
" In the present study, we investigated the cardioprotective effects and pharmacokinetic properties of a controlled release formulation of SPRC (CR-SPRC) in an in vivo rat model of myocardial infarction (MI)."	( Cardioprotective effects and pharmacokinetic properties of a controlled release formulation of a novel hydrogen sulfide donor in rats with acute myocardial infarction. Huang, C; Lin, S; Liu, H; Liu, X; Tran, BH; Wang, S; Zhang, Q; Zhu, YZ, 2015)	0.42

Excerpt	Reference	Relevance
" The bioavailability after oral administration at 25, 75, and 225 mg/kg was 96."	( Determination of S-propargyl-cysteine in rat plasma by mixed-mode reversed-phase and cation-exchange HPLC-MS/MS method and its application to pharmacokinetic studies. Cai, W; Gu, Y; Liu, H; Ma, G; Shao, T; Yang, P; Zhang, L; Zhang, P; Zheng, Y; Zhu, Q; Zhu, Y, 2011)	0.37
" Bioavailability and pharmacokinetics of SPRC (20 mg/kg) in beagle dogs after oral and intravenous administrations were investigated in this study."	( Bioavailability and pharmacokinetics of S-propargyl-L-cysteine, a novel cardioprotective agent, after single and multiple doses in Beagle dogs. Cai, W; Liu, H; Ma, G; Xu, J; Zhang, J; Zhang, P; Zheng, Y; Zhu, Q; Zhu, Y, 2012)	0.38
" Absorption rate constants (ka), hourly absorption percentage (P) and apparent permeability coefficient (Papp) of SPRC in the small intestine were ≥0."	( Physicochemical characteristics and gastrointestinal absorption behaviors of S-propargyl-cysteine, a potential new drug candidate for cardiovascular protection and antitumor treatment. Bao, X; Bu, F; Cai, W; Huang, W; Liu, H; Ma, G; Shi, Q; Wang, F; Zhang, L; Zhang, P; Zhang, Y; Zheng, Y; Zhou, N; Zhu, Y, 2015)	0.42

Bioassays (8)

Assay ID	Title	Year	Journal	Article
AID539383	Cardioprotective activity against hypoxia-induced neonatal rat ventricular myocytes damage assessed as increase in hydrogen sulfide level at 10 uM treated 12 hrs before hypoxia challenge measured after 5 hrs	2010	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23	Synthesis and biological evaluation of novel leonurine-SPRC conjugate as cardioprotective agents.
AID539394	Cardioprotective activity against hypoxia-induced neonatal rat ventricular myocytes damage assessed as decrease of creatine kinase release at 10 uM treated 12 hrs before hypoxia challenge measured after 5 hrs	2010	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23	Synthesis and biological evaluation of novel leonurine-SPRC conjugate as cardioprotective agents.
AID1599998	Antagonist activity at TLR2 in mouse RAW264.7 cells assessed as PAM3CSK4-induced NO production at 150 uM measured after 24 hrs by Griess assay	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Structure-activity relationship study and biological evaluation of SAC-Garlic acid conjugates as novel anti-inflammatory agents.
AID626999	Cardioprotective activity against hypoxia-induced Sprague-Dawley NRVM damage assessed as increased cell viability at 0.1 uM treated 12 hrs before hypoxia challenge measured after 5 hrs by MTT assay	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Leonurine-cysteine analog conjugates as a new class of multifunctional anti-myocardial ischemia agent.
AID539392	Cardioprotective activity against hypoxia-induced neonatal rat ventricular myocytes damage assessed as decrease of LDH release at 10 uM treated 12 hrs before hypoxia challenge measured after 5 hrs	2010	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23	Synthesis and biological evaluation of novel leonurine-SPRC conjugate as cardioprotective agents.
AID627001	Cardioprotective activity against hypoxia-induced Sprague-Dawley NRVM damage assessed as increase in hydrogen sulfide level at 0.1 uM treated 12 hrs before hypoxia challenge measured after 5 hrs	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Leonurine-cysteine analog conjugates as a new class of multifunctional anti-myocardial ischemia agent.
AID539390	Cardioprotective activity against hypoxia-induced neonatal rat ventricular myocytes damage assessed as increased cell viability at 10 uM treated 12 hrs before hypoxia challenge measured after 5 hrs by MTT assay	2010	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23	Synthesis and biological evaluation of novel leonurine-SPRC conjugate as cardioprotective agents.
AID627000	Cardioprotective activity against hypoxia-induced Sprague-Dawley NRVM damage assessed as inhibition of LDH release at 0.1 uM treated 12 hrs before hypoxia challenge measured after 5 hrs	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Leonurine-cysteine analog conjugates as a new class of multifunctional anti-myocardial ischemia agent.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (4.00)	29.6817
2010's	24 (96.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (4.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	24 (96.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
4-hydroxybenzoic acid 4-hydroxybenzoic acid : A monohydroxybenzoic acid that is benzoic acid carrying a hydroxy substituent at C-4 of the benzene ring.	2.21	1	monohydroxybenzoic acid	algal metabolite; plant metabolite
gallic acid gallate : A trihydroxybenzoate that is the conjugate base of gallic acid.	2.21	1	trihydroxybenzoic acid	antineoplastic agent; antioxidant; apoptosis inducer; astringent; cyclooxygenase 2 inhibitor; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; geroprotector; human xenobiotic metabolite; plant metabolite
hydrogen sulfide Hydrogen Sulfide: A flammable, poisonous gas with a characteristic odor of rotten eggs. It is used in the manufacture of chemicals, in metallurgy, and as an analytical reagent. (From Merck Index, 11th ed). hydrogen sulfide : A sulfur hydride consisting of a single sulfur atom bonded to two hydrogen atoms. A highly poisonous, flammable gas with a characteristic odour of rotten eggs, it is often produced by bacterial decomposition of organic matter in the absence of oxygen.. thiol : An organosulfur compound in which a thiol group, -SH, is attached to a carbon atom of any aliphatic or aromatic moiety.	5.33	16	gas molecular entity; hydracid; mononuclear parent hydride; sulfur hydride	Escherichia coli metabolite; genotoxin; metabolite; signalling molecule; toxin; vasodilator agent
alpha-resorcylic acid alpha-resorcylic acid: RN given refers to parent cpd. 3,5-dihydroxybenzoic acid : A dihydroxybenzoic acid in which the hydroxy groups are located at positions 3 and 5.	2.21	1	dihydroxybenzoic acid; resorcinols	metabolite
3,4,5-trimethoxybenzoic acid 3,4,5-trimethoxybenzoic acid: RN given refers to parent cpd; structure. 3,4,5-trimethoxybenzoic acid : A benzoic acid derivative carrying 3-, 4- and 5-methoxy substituents.	2.21	1	benzoic acids; methoxybenzenes	human urinary metabolite; human xenobiotic metabolite; plant metabolite
leonurine leonurine: has neuroprotective activity; isolated from leaves of Leonurus artemisia; has uterotonic effect; structure	2.46	2	trihydroxybenzoic acid
s-benzylcysteine [no description available]	2.21	1	S-aryl-L-cysteine zwitterion
cysteine Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.	5.63	22	cysteinium	fundamental metabolite
s-allylcysteine S-allylcysteine: structure in first source; RN given refers to (L)-isomer. S-allylcysteine : An S-hydrocarbyl-L-cysteine that is L-cysteine in which the hydrogen attached to the sulphur is replaced by a prop-2-enyl group. It commonly occurs in garlic and has been found to exhibit antineoplastic activity.	2.21	1	L-alpha-amino acid zwitterion; S-hydrocarbyl-L-cysteine	antineoplastic agent; metabolite
mocetinostat mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).	2.07	1	aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline	antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent
ceruletide Ceruletide: A specific decapeptide obtained from the skin of Hila caerulea, an Australian amphibian. Caerulein is similar in action and composition to CHOLECYSTOKININ. It stimulates gastric, biliary, and pancreatic secretion; and certain smooth muscle. It is used in paralytic ileus and as diagnostic aid in pancreatic malfunction.. ceruletide : A decapeptide comprising 5-oxoprolyl, glutamyl, aspartyl, O-sulfotyrosyl, threonyl, glycyl, tryptopyl, methionyl, aspartyl and phenylalaninamide residues in sequence. Found in the skins of certain Australian amphibians, it is an analogue of the gastrointestinal peptide hormone cholecystokinin and stimulates gastric, biliary, and pancreatic secretion. It is used in cases of paralysis of the intestine (paralytic ileus) and as a diagnostic aid in pancreatic malfunction.	2.07	1	oligopeptide	diagnostic agent; gastrointestinal drug

Condition	Relationship Strength	Studies
Anoxemia [description not available]	2.05	1
Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms.	2.05	1
Heart Disease, Ischemic [description not available]	3.91	4
Myocardial Ischemia A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).	3.91	4
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	3.48	7
Cirrhosis [description not available]	2.53	2
Cardiac Failure [description not available]	3.73	3
Fibrosis Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.	7.53	2
Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.	8.73	3
Angiogenesis, Pathologic [description not available]	2.1	1
Alloxan Diabetes [description not available]	2.52	2
Diabetic Cardiomyopathies Diabetes complications in which VENTRICULAR REMODELING in the absence of CORONARY ATHEROSCLEROSIS and hypertension results in cardiac dysfunctions, typically LEFT VENTRICULAR DYSFUNCTION. The changes also result in myocardial hypertrophy, myocardial necrosis and fibrosis, and collagen deposition due to impaired glucose tolerance.	2.11	1
Cancer of Pancreas [description not available]	2.11	1
Carcinoma, Ductal, Pancreatic [description not available]	2.11	1
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	2.11	1
Carcinoma, Pancreatic Ductal Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.	2.11	1
Cardiovascular Stroke [description not available]	2.48	2
Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).	2.48	2
Diabetic Glomerulosclerosis [description not available]	2.13	1
Nephritis Inflammation of any part of the KIDNEY.	2.13	1
Diabetic Nephropathies KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.	2.13	1
Cardiac Toxicity [description not available]	2.13	1
Cardiotoxicity Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.	7.13	1
Innate Inflammatory Response [description not available]	2.78	3
Anemia A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.	7.13	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	7.78	3
Rheumatoid Arthritis [description not available]	7.13	1
Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.	2.13	1
Academic Disorder, Developmental [description not available]	2.06	1
Age-Related Memory Disorders [description not available]	2.06	1
Learning Disabilities Conditions characterized by a significant discrepancy between an individual's perceived level of intellect and their ability to acquire new language and other cognitive skills. These may result from organic or psychological conditions. Relatively common subtypes include DYSLEXIA, DYSCALCULIA, and DYSGRAPHIA.	2.06	1
Memory Disorders Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions.	2.06	1
Cancer of Stomach [description not available]	2.06	1
Stomach Neoplasms Tumors or cancer of the STOMACH.	2.06	1
Atherogenesis [description not available]	2.07	1
Angiitis [description not available]	2.07	1
Vasculitis Inflammation of any one of the blood vessels, including the ARTERIES; VEINS; and rest of the vasculature system in the body.	2.07	1
Atherosclerosis A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.	2.07	1
Acute Edematous Pancreatitis [description not available]	2.07	1
Acute Disease Disease having a short and relatively severe course.	2.07	1
Pancreatitis INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.	7.07	1

s-propargylcysteine

Description

Cross-References

Synonyms (20)

Research Excerpts

Pharmacokinetics

Bioavailability

Bioassays (8)

Research

Studies (25)

Market Indicators

Research Demand Index: 12.55

Study Types

s-propargylcysteine

Description

Cross-References

Synonyms (20)

Research Excerpts

Pharmacokinetics

Bioavailability

Bioassays (8)

Research

Studies (25)

Market Indicators

Research Demand Index: 12.55

Study Types

Related Drugs (11)

Related Conditions (41)